The German biotech is focused internally on a strategic set of respiratory disorders, and works with partners to realize the potential for its patented SNIM RNA transcript therapies in various areas of human disease.

In 2017, Ethris announced a five-year strategic research collaboration with AstraZeneca focused on developing new stabilized non-immunogenic modified RNA therapies for respiratory diseases using SNIM RNA technology.